Skip to main content

Table 3 Clinical trials for younger patients with MCL

From: Current trials for frontline therapy of mantle cell lymphoma

Leading institution

PI last name

Regimen

Study ID/NCT

EE

Phase

Line

Recruitment

First received

Study results

Cytogenetical inclusion criteria

Age group (years)

IHBDH

Yi

R-EDOCH/R-DHAP → HDT/ASCR

or

R-EDOCH/R-DHAP → MR or MTp

IIT2015007-EC-1

BDH-MCL01

NCT02858804

55

IV

1st

Recruiting

7/17/2016

NA

Not specified

18–65

WUSM

Kahl

BR/RAC

201603149

NCT02728531

15

I

1st

Recruiting

03/30/2016

NA

t(11;14) and/or CCND1 overex

18–65

MDACC

Wang

RI → Hyper-CVAD

WINDOW I

NCT02427620

100

II

1st

Recruiting

4/15/2015

Preliminary [46]

CRR 100%

mOS and mPFS NR

Blastoid or pleomorphic or, Ki-67 ≥ 30% or mutation TP53, c-MYC or NOTCH

18–65

RPCI

Hernandez-Ilizaliturri

O-HyperCVAD/O-MA

I 201611

NCT01527149

37

II

1st

Recruiting

12/12/2011

NA

t(11;14) and/or CCND1 overex and/or bcl-1/IgH rearragement

18–70

MSKCC

Zelenetz

R-CHOP14 → R-HIDAC → RIT → HDT → ASCR

11-095

NCT01484093

96

I and II

1st

Active, not rec

11/29/2011

NA

CCND1 or D2 or D3 positive

18–70

  1. ASCT autologous stem cell transplant; bcl-1 B cell leukemia/lymphoma 1; CCND1 cyclin D1; CHT chemotherapy; CRR complete response rate; EE estimated enrollment; HDT/ASCR high-dose chemotherapy and autologous stem cell rescue; ID identification; IgH immunoglobulin heavy locus; IHBDH Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College; MA high-dose cytarabine and methotrexate; mOS median overall survival; mPFS median progression-free survival; MR maintenance rituximab; MSKCC Memorial Sloan Kettering Cancer Center; MTp maintenance thalidomide and prednisone; MV maintenance bortezomib; NA not available; NCT clinical trial number registered at clinicaltrials.gov; NR not reached; O ofatumumab; overex overexpression; PI principal investigator; R rituximab; RAC rituximab and cytarabine; R-CHOP-14 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone every 2 weeks; rec recruiting; R-DHAP rituximab cisplatin, cytosine arabinoside, and dexamethasone; R-EDOCH rituximab etoposide, dexamethasone, doxorubicin, cyclophosphamide, and vincristine; R-HIDAC rituximab and high-dose cytarabine; RI → Hyper-CVAD rituximab ibrutinib followed by hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; RIT radioimmunotherapy Iodine 131I Tositumomab; RPCI Roswell Park Cancer Institute; t translocation; UCSF University of California, San Francisco; V bortezomib; WUSM Washington University School of Medicine